Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,089 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mass, Spectroscopy, and Two-Neutron Decay of ^{16}Be.
Monteagudo B, Marqués FM, Gibelin J, Orr NA, Corsi A, Kubota Y, Casal J, Gómez-Camacho J, Authelet G, Baba H, Caesar C, Calvet D, Delbart A, Dozono M, Feng J, Flavigny F, Gheller JM, Giganon A, Gillibert A, Hasegawa K, Isobe T, Kanaya Y, Kawakami S, Kim D, Kiyokawa Y, Kobayashi M, Kobayashi N, Kobayashi T, Kondo Y, Korkulu Z, Koyama S, Lapoux V, Maeda Y, Motobayashi T, Miyazaki T, Nakamura T, Nakatsuka N, Nishio Y, Obertelli A, Ohkura A, Ota S, Otsu H, Ozaki T, Panin V, Paschalis S, Pollacco EC, Reichert S, Rousse JY, Saito AT, Sakaguchi S, Sako M, Santamaria C, Sasano M, Sato H, Shikata M, Shimizu Y, Shindo Y, Stuhl L, Sumikama T, Sun YL, Tabata M, Togano Y, Tsubota J, Uesaka T, Yang ZH, Yasuda J, Yoneda K, Zenihiro J. Monteagudo B, et al. Among authors: ozaki t. Phys Rev Lett. 2024 Feb 23;132(8):082501. doi: 10.1103/PhysRevLett.132.082501. Phys Rev Lett. 2024. PMID: 38457706 Free article.
Magicity versus Superfluidity around ^{28}O viewed from the Study of ^{30}F.
Kahlbow J, Aumann T, Sorlin O, Kondo Y, Nakamura T, Nowacki F, Revel A, Achouri NL, Al Falou H, Atar L, Baba H, Boretzky K, Caesar C, Calvet D, Chae H, Chiga N, Corsi A, Delaunay F, Delbart A, Deshayes Q, Dombrádi Z, Douma CA, Elekes Z, Gašparić I, Gheller JM, Gibelin J, Gillibert A, Harakeh MN, Hirayama A, Holl M, Horvat A, Horváth Á, Hwang JW, Isobe T, Kalantar-Nayestanaki N, Kawase S, Kim S, Kisamori K, Kobayashi T, Körper D, Koyama S, Kuti I, Lapoux V, Lindberg S, Marqués FM, Masuoka S, Mayer J, Miki K, Murakami T, Najafi M, Nakano K, Nakatsuka N, Nilsson T, Obertelli A, Orr NA, Otsu H, Ozaki T, Panin V, Paschalis S, Rossi DM, Saito AT, Saito T, Sasano M, Sato H, Satou Y, Scheit H, Schindler F, Schrock P, Shikata M, Shimada K, Shimizu Y, Simon H, Sohler D, Stuhl L, Takeuchi S, Tanaka M, Thoennessen M, Törnqvist H, Togano Y, Tomai T, Tscheuschner J, Tsubota J, Uesaka T, Wang H, Yang Z, Yasuda M, Yoneda K; SAMURAI21-NeuLAND Collaboration. Kahlbow J, et al. Among authors: ozaki t. Phys Rev Lett. 2024 Aug 23;133(8):082501. doi: 10.1103/PhysRevLett.133.082501. Phys Rev Lett. 2024. PMID: 39241734
Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial.
Tokunaga E, Iwata H, Itoh M, Taira T, Toyama T, Mizuno T, Osaki A, Yanagita Y, Nakamura S, Nakamura R, Sambe T, Ozaki T, Schiavon G, Howell SJ, Toi M. Tokunaga E, et al. Among authors: ozaki t. Breast Cancer. 2024 Oct 8. doi: 10.1007/s12282-024-01640-z. Online ahead of print. Breast Cancer. 2024. PMID: 39379782
2,089 results